Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market Company anticipates full data analysisby the end of March 2026; data to ...
At Parametric, we’ve observed more asset owners adopt a Total Portfolio Approach, enabling them to manage risk and return holistically. Increasingly, they seek partners with deep cross-asset expertise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results